Zymeworks Inc. Stock

ZYME

US98985Y1082

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 02:26:36 2024-04-24 pm EDT			5-day change	1st Jan Change
8.575 ^USD	+0.18%		-3.11%	-17.47%

Apr. 08	Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	CI
Apr. 04	Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	CI

Latest news about Zymeworks Inc.

Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	Apr. 08	CI
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	Apr. 04	CI
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President	Apr. 04	CI
Zymeworks Inc. Announces the Composition of the Committees	Mar. 28	CI
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024	Mar. 28	CI
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	Mar. 12	MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	Mar. 11	MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	Mar. 05	CI
Zymeworks Inc. Appoints Scott Platshon as Director	Feb. 22	CI
Transcript : Zymeworks Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-22-2024 08:00 AM	Feb. 22
Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors	Feb. 08	CI
Transcript : Zymeworks Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	Jan. 11

More news

Latest transcript on Zymeworks Inc.

Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024

Mar. 06

More transcripts

Analyst Recommendations on Zymeworks Inc.

Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	Mar. 12	MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	Mar. 11	MT
Citigroup Adjusts Price Target on Zymeworks to $18 From $17, Keeps Buy Rating	23-05-18	MT
Stifel Adjusts Price Target on Zymeworks to $19 From $18, Maintains Buy Rating	23-05-09	MT
JPMorgan Raises Zymeworks' Price Target to $9 From $8, Keeps Neutral Rating	23-03-31	MT

More recommendations

News in other languages on Zymeworks Inc.

Zymeworks : obtient la désignation de médicament orphelin de la Commission européenne pour le zanidatamab, un anticorps bispécifique ciblant le HER2, dans le traitement du cancer gastrique	20-11-19
Zymeworks : erhält Orphan-Drug-Status von der Europäischen Kommission für den gegen HER2 gerichteten, bispezifischen Antikörper Zanidatamab bei Patienten mit Magenkrebs	20-11-19

More news

Highs and lows

1 week

8.54

8.98

1 month

8.54

10.61

Current year

8.54

13.14

1 year

6.02

13.14

3 years

4.11

39.41

5 years

4.11

59.03

10 years

4.11

59.03

More quotes

ETFs positioned on Zymeworks Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.04%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.03%	0 M€	0.00%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.00%	34 M€	+2.14%	-

More ETFs positioned on Zymeworks Inc.

Quotes

Date	Price	Change	Volume
24-04-24	8.575	+0.18%	121 224
24-04-23	8.56	-1.72%	486,733
24-04-22	8.71	-1.58%	719,984
24-04-19	8.85	+2.08%	1,002,678
24-04-18	8.67	-2.03%	731,698

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Zymeworks Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.56 USD

Average target price

14.17 USD

Spread / Average Target

+65.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZYMEWORKS INC.	-17.61%	604M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.00%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.22%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs

Sales 2024 *	88.9M	Sales 2025 *	112M	Capitalization	604M
Net income 2024 *	-65M	Net income 2025 *	-43M	EV / Sales 2024 *	3.47 x
Net cash position 2024 *	296M	Net cash position 2025 *	355M	EV / Sales 2025 *	2.22 x
P/E ratio 2024 *	-7.61 x	P/E ratio 2025 *	-9.4 x	Employees	275
Yield 2024 *	-	Yield 2025 *	-	Free-Float	93.13%

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 20	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 12	PR
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024	Apr. 11	GL
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting	Apr. 08	GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 04	PR

1 day	-1.72%
1 week	-4.14%
Current month	-18.63%
1 month	-18.63%
3 months	-16.73%
6 months	+22.29%
Current year	-17.61%

Zymeworks Inc. Stock

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Financials (USD)

Chart Zymeworks Inc.

Latest news about Zymeworks Inc.

Latest transcript on Zymeworks Inc.

Analyst Recommendations on Zymeworks Inc.

Press releases Zymeworks Inc.

News in other languages on Zymeworks Inc.

Quotes and Performance

Highs and lows

ETFs positioned on Zymeworks Inc.

Quotes

Company Profile

Income Statement Evolution

Ratings for Zymeworks Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs